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FOXO transcription factors protect 
against the diet-induced fatty liver 
disease
Xiaoyan Pan1,2,*, Yang Zhang2,*, Hyeong-Geug Kim2, Suthat Liangpunsakul3,4 & 
X. Charlie Dong2
Forkhead O transcription factors (FOXOs) have been implicated in glucose and lipid homeostasis; 
however, the role of FOXOs in the development of nonalcoholic fatty liver disease (NAFLD) is not well 
understood. In this study, we designed experiments to examine the effects of two different diets—very 
high fat diet (HFD) and moderately high fat plus cholesterol diet (HFC)—on wildtype (WT) and liver-
specific Foxo1/3/4 triple knockout mice (LTKO). Both diets induced severe hepatic steatosis in the LTKO 
mice as compared to WT controls. However, the HFC diet led to more severe liver injury and fibrosis 
compared to the HFD diet. At the molecular levels, hepatic Foxo1/3/4 deficiency triggered a significant 
increase in the expression of inflammatory and fibrotic genes including Emr1, Ccl2, Col1a1, Tgfb, 
Pdgfrb, and Timp1. Thus, our data suggest that FOXO transcription factors play a salutary role in the 
protection against the diet-induced fatty liver disease.
Forkhead O transcription factors (FOXOs) play a critical role in the integration of hormonal and nutritional sig-
nals for metabolic control1. As a downstream mediator of insulin signaling, the activity of FOXOs is modulated 
by serine/threonine phosphorylation catalyzed by Akt and other kinases. This insulin-mediated regulation has 
been implicated in the metabolic control during fasting and feeding cycles. In general, during feeding FOXOs 
are largely inhibited by the insulin-stimulated Akt whereas during fasting FOXOs are less phosphorylated and 
actively promote gluconeogenesis and lipolysis and inhibit glycolysis and lipogenesis2–13.
With regard to hepatic lipid metabolism, FOXOs play a key role in integrating multiple pathways. FOXOs 
have been shown to inhibit lipogenesis through suppression of genes such as sterol regulatory element binding 
protein 1c (SREBP-1c) and glucokinase6,14–19. FOXOs also interplay with sirtuin proteins, especially SIRT1 and 
SIRT66,7,20–25. As sirtuins are NAD-dependent enzymes, FOXOs have been shown to modulate sirtuin activities 
through control of expression of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme 
in the NAD biosynthesis8. Both SIRT1 and SIRT6 have been shown to inhibit lipogenesis and promote fatty 
acid oxidation in the liver24. FOXOs also promote hepatic lipolysis by upregulation of adipose triglyceride lipase 
(ATGL) that catalyzes the first step of lipolysis and downregulation of the G0/S1 switch 2 gene (G0S2), an inhibi-
tor of ATGL4. In addition, FOXOs also increase breakdown of lipid droplets through activation of the autophagy 
pathway as autophagy related 14 (ATG14) has been shown to be a direct target of FOXOs26.
Both endogenous and exogenous factors can cause dysregulation of hepatic lipid homeostasis. One of the 
critical environmental factors is diet. It has been shown that diets containing excessive amount of fat, especially 
saturated fatty acids, remarkably increase the risk of obesity and nonalcoholic fatty liver disease (NAFLD)27–30. 
Additionally, dietary cholesterol has been attributed to the development of NAFLD27,31–36. We have recently 
reported that FOXOs regulate both total cholesterol and low-density lipoprotein cholesterol7,25. Generally, 
NAFLD is a progressive liver disease, beginning with simple steatosis, progressing to nonalcoholic steatohepatitis 
(NASH) and fibrosis, and in some cases ending up as cirrhosis and hepatocellular carcinoma37. Understanding 
the mechanism and pathogenesis leading to hepatic steatosis or NASH is of importance, as early interventions will 
likely either delay or reverse the disease progression.
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To better understand the gene (notably FOXOs)-environment (different types of diets) interaction in the 
development of NAFLD, we set out to characterize wildtype (WT) and Foxo1/3/4 liver-specific triple knockout 
mice (LTKO) that were fed either regular chow, simply high-fat or moderately high-fat plus cholesterol diet.
Results
Dietary effects on food intake, body weight, liver, and adipose depot. Foxo1/3/4 gene knockout 
in the liver was confirmed by real-time PCR and immunoblotting (Fig. 1A–D). It was also noteworthy that both 
Foxo1 and Foxo3 genes were downregulated at both mRNA and protein levels in the liver of WT mice fed the 
HFC diet. Food intake measured by kcal/day was not significantly different among different dietary groups, but 
the HFD group gained more weight compared to the chow and HFC groups (Fig. 2A and B). The ratio of liver to 
body weight was increased nearly 2-fold in the LTKO mice as compared to the WT mice under the HFC dietary 
condition (p = 0.00045, Fig. 2C). Although there is a trend of increase in the HFD group, the ratio of perigonadal 
fat pad to body weight was not statistically different among three dietary groups (Fig. 2D).
Diet and gene effects on serum triglyceride, cholesterol, and alanine aminotransferase 
(ALT). Serum triglyceride (TG) levels were significantly higher in the LTKO mice compared to the WT mice 
among all three dietary groups (p = 0.018, p = 0.022, and p = 0.023, respectively), but there was no significant 
effect by diet within the same genotype (Fig. 3A). Serum cholesterol levels were also elevated in the LTKO mice 
relative to the WT mice for the chow and HFC groups (p = 0.045 and p = 0.009, respectively, Fig. 3B). Serum 
ALT is often used a marker for liver injury. Interestingly, serum ALT levels were significantly affected by both 
Foxo1/3/4 deficiency and diets (p = 0.003, p = 0.012, and p = 0.003 for LTKO vs. WT in chow, HFD, and HFC, 
respectively; p = 0.05, p < 0.0001, and p = 0.012 for LTKO mice chow vs. HFD, chow vs. HFC, and HFD vs. HFC, 
respectively). The LTKO mice fed with the HFC diet had the highest level of serum ALT, followed by those fed 
with the HFD and chow diets (Fig. 3C).
Effects on hepatic steatosis and fibrosis. Liver sections were stained by hematoxylin and eosin for his-
tological analysis. As shown in Fig. 4A, LTKO livers had increased lipid droplet accumulation in all three dietary 
conditions. However, liver tissues from mice fed with the HFC diet showed the worst hepatic steatosis with numer-
ous large lipid droplets. Biochemical analysis of hepatic triglyceride contents also confirmed the steatosis phe-
notype in the LTKO mice under either HFD or HFC diet (Fig. 4B). Histological analysis also revealed increased 
hepatic steatosis and inflammation in the LTKO mice using the numerical scoring systems (Fig. 4C and D). 
Sirius Red stain was used to examine the presence of liver fibrosis. As shown in Fig. 5, fibrosis was increased in 
both HFD and HFC groups compared to the chow group. Foxo1/3/4 deficiency further exacerbated the extent 
Figure 1. Generation of Foxo1/3/4 liver-specific knockout mice (LTKO). (A–C) Real-time PCR analysis 
of Foxo1, Foxo3, and Foxo4 mRNAs in the WT and LTKO mouse livers (n = 3), respectively *p < 0.05. (D) 
Western blot analysis of Foxo1 and Foxo3 proteins in WT and LTKO livers. The blots for the proteins shown are 
in the cropped format, and the full-length blots are presented in the Supplementary Figure 1. As Foxo4 protein 
is barely detectable in the mouse liver, Foxo4 Western blot data were not presented.
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of fibrosis in all dietary groups, especially in those fed with HFC, which showed a remarkable increase in fibrosis 
(Fig. 5).
Effects on hepatic gene expression. To assess the molecular changes that lead to the phenotypic dif-
ferences among the three dietary groups, we performed real-time PCR and Western blot analyses to determine 
differential expression of genes known to be involved in lipid metabolism and fibrogenesis. First, we examined 
the lipogenic genes including a key regulator Srebp1c and acetyl-CoA carboxylase 1 (Acc1). Although Srebp1c 
mRNA levels were increased in the liver of the HFC-treated mice, but they did not reach a statistical significance 
as compared to those fed with chow and HFD (Fig. 6A). Second, we analyzed genes that are involved in fatty 
acid oxidation – carnitine palmitoyltransferase 1a (Cpt1a) and acyl-CoA oxidase 2 (Acox2). Expression of Cpt1a 
was significantly decreased in the liver of the HFC-treated mice whereas Acox2 mRNA levels were decreased in 
the liver of the HFD-treated mice as compared to the Chow-WT mice (Fig. 6C and D). Third, as inflammation 
is a critical factor in the progression of fatty liver disease from simple steatosis to NASH, we also analyzed two 
inflammatory marker genes - adhesion G protein-coupled receptor E1 (Adgre1, also named Emr1 or F4/80) and 
chemokine (C-C motif) ligand 2 (Ccl2, also named MCP-1). Expression of the Emr1 gene in the WT livers was 
induced by either HFD or HFC diet whereas it was further elevated in the HFC-treated LTKO mouse livers 
(Fig. 7A). The hepatic Ccl2 mRNA levels were elevated in the LTKO mice compared to the WT mice under the 
chow diet condition but they did not reach a statistical significance. Fourth, we analyzed a few genes that are 
involved in the pathogenesis of hepatic fibrosis. Expression of platelet derived growth factor receptor, beta pol-
ypeptide (Pdgfrb) was elevated in the LTKO livers and further induced by the HFC diet (Fig. 7C). The HFC diet 
also significantly induced expression of the transforming growth factor beta gene (Tgfb) in both WT and LTKO 
livers (Fig. 7D). Hepatic expression of the type 1, alpha 1 collagen gene (Col1a1) was induced by either HFD or 
HFC, and Foxo1/3/4 deficiency further enhanced the Col1a1 gene expression (Fig. 7E). Like the Col1a1 gene, 
expression of the tissue inhibitor of metalloproteinase 1 gene (Timp1) was also induced by HFD or HFC and 
the Foxo1/3/4 gene knockout (Fig. 7F). The upregulation of the Pdgfrb and Tgfb genes was also confirmed at the 
protein levels (Fig. 7G).
Hepatic neutrophil infiltration is one of the hallmark features in NASH. We performed immunohistochem-
istry (IHC) analysis of liver sections using a common neutrophil marker – myeloperoxidase (MPO). Both HFD 
and HFC increased the neutrophil infiltration in WT and LTKO mouse livers, but the LTKO mice exhibited more 
severe inflammation evidenced by the increased MPO staining intensity (Fig. 8A and B). Since NASH also mani-
fests hepatic fibrosis, we also analyzed two fibrosis markers — alpha-smooth muscle actin (α -SMA) and TIMP1, 
Figure 2. Animal food intake and body weight. (A) Food intake measurements. (B) Body weight 
measurements (n = 7, *p < 0.05 for Chow-WT vs. HFD-WT, Chow-LTKO vs. HFD-LTKO, HFC-WT vs. 
HFD-WT, HFC-LTKO vs. HFD-WT, and HFC-LTKO vs. HFD-LTKO). (C) Liver/body weight ratio (n = 7, 
*p < 0.05 for chow groups, #p < 0.001 for HFC groups). (D) Perigonadal fat/body weight ratio in WT and LTKO 
mice that were fed chow, HFD, or HFC diet (n = 7).
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in liver sections. In comparison to WT mice, LTKO mice on both HFD and HFC diets showed more pronounced 
fibrosis demonstrated by the elevated α -SMA and TIMP1 staining intensity (Fig. 9A–D).
Discussion
In this work, we have demonstrated two critical factors that significantly contribute to the pathogenesis of 
NAFLD. The first factor is intrinsic – the function of FOXO transcription factors. FOXOs, especially FOXO3, have 
implicated in animal longevity and metabolic homeostasis38. Our data from the Foxo1/3/4-LTKO mice indicate 
that deletion of FOXO1/3/4 genes exacerbates diet-induced hepatic steatosis and liver injury, suggesting a protec-
tive role of FOXOs in the liver. The second factor is extrinsic or environmental – the diet composition. Not simply 
high content of saturated fat but moderately high content of fat plus cholesterol poses a higher risk for NAFLD.
From the biological functions of FOXOs, we are not surprised to see that FOXOs have protective effects on 
the development of NAFLD. There are several factors that contribute to the pathogenesis of steatosis: increased 
lipogenesis, increased uptake of free fatty acids, or decreased triglyceride breakdown or secretion in a form 
of VLDL39. Data from our laboratory and others have shown that FOXOs play a critical role in hepatic lipid 
homeostasis by inhibiting lipogenesis and increasing triglyceride breakdown3–5,8,14,17,19,26,40. In this work, we have 
observed that the expression of lipogenic and fatty acid oxidation genes is modulated by both FOXOs and diets. 
For example, the Cpt1a gene is significantly downregulated in HFC-treated LTKO livers whereas the Acox2 gene 
was decreased in the HFD-treated LTKO livers. In addition, FOXO1 and FOXO6 have been shown to promote 
VLDL production in the liver by activating the expression of the microsomal triglyceride transfer protein41,42. 
Whether VLDL production is altered in the LTKO liver requires further investigation.
In recent years, cholesterol has been increasingly appreciated as a significant risk factor for NAFLD. A retro-
spective epidemiological study reveals that the ratio of total cholesterol to HDL-cholesterol is a significant risk 
factor for advanced NAFLD31. The association of cholesterol with NAFLD has also been reported in other stud-
ies33,43–45. In one study, C57BL/6 J mice fed with 45% fat (by calorie) plus 0.2% cholesterol diet for 4 months man-
ifest phenotypic features of NASH and fibrosis46. In another study, Sprague-Dawley rats were fed either a high-fat 
diet (30% palm oil), high-fat (28.75% palm oil) plus 1.25% cholesterol diet, or high-fat (27.5% palm oil) plus 2.5% 
cholesterol diet for 9 weeks34. The results are very similar to our data that the cholesterol-containing diets remark-
ably promote progression from simple steatosis to NASH. More significantly, the 2.5% cholesterol-containing 
Figure 3. Blood chemistry analysis. (A–C) Serum triglyceride, cholesterol, and ALT in WT and LTKO mice 
that were fed with chow, HFD, or HFC diet, respectively. Values are expressed as mean ± SEM, n = 7 per group. 
*p < 0.05 for WT vs. LTKO, #p < 0.05 for HFC vs. Chow or HFD in LTKO mice.
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Figure 4. Hepatic steatosis and inflammation in WT and LTKO mice fed with different diets. (A) Liver 
sections were stained using H&E and imaged at a magnification of 200 × . (B) Hepatic triglycerides was 
analyzed in the liver of WT and LTKO mice that were fed with chow, HFD, or HFC diet. Values are expressed 
as mean ± SEM, n = 3–4 for each group. *p < 0.05 and ***p < 0.001 for WT vs. LTKO, ##p < 0.01 for HFC or 
HFD vs. Chow in LTKO mice. $p < 0.05 and $$$p < 0.001 for HFC or HFD vs. Chow in WT. ¶p < 0.05 for HFC 
vs. HFD in LTKO. The scores of hepatic steatosis (C) and inflammation (D) were analyzed in WT and LTKO 
mice fed with chow, HFD, or HFC diet. Values are expressed as mean ± SEM, n = 4 for each group. *p < 0.05 and 
***p < 0.001 for WT vs. LTKO, #p < 0.05 and ##p < 0.01 for HFC or HFD vs. Chow in LTKO mice. $p < 0.05 and 
$$p < 0.01 for HFC or HFD vs. Chow in WT. ¶p < 0.05 and ¶¶p < 0.01 for HFC vs. HFD in LTKO.
www.nature.com/scientificreports/
6Scientific RepoRts | 7:44597 | DOI: 10.1038/srep44597
diet induces liver cirrhosis in 40% of rats34. However, the underlying mechanisms on high cholesterol diet causing 
NASH are not well understood. Excess hepatic free cholesterol is believed to have adverse effects on hepatocytes, 
Kupffer cells and hepatic stellate cells, including alteration of cell membrane fluidity and membrane protein func-
tion, endoplasmic reticulum stress, mitochondrial dysfunction, and activation of Kupffer and stellate cells32,47–51. 
Knockout of Foxo1/3 or Foxo1/3/4 in the mouse liver leads to elevated hepatic free cholesterol levels7,40, suggest-
ing that FOXOs play a critical role in hepatic cholesterol homeostasis. As demonstrated in this work, deletion of 
hepatic Foxo1/3/4 markedly aggravates the NAFLD phenotype by increasing hepatic inflammation and fibrosis, 
especially on the HFC diet.
Although we have attempted to address both gene and dietary effects on the development of NAFLD, the 
diet-gene interplay is much more complicated than what we have presented here. First of all, diets have global 
effects on the animal system, including key organs involved in the metabolic homeostasis like brain, pancreas, 
intestine, muscle, and adipose tissue52,53. Second, both central and peripheral organs can impact liver physiol-
ogy through inter-organ crosstalks53. For instance, white adipose tissue has strong interaction with hepatic lipid 
metabolism53–55. How those systemic and tissue-secreted factors may influence hepatic FOXO activity will be very 
interesting to be investigated in the future study.
In summary, our data reveals an important role of FOXO transcription factors in hepatic lipid homeostasis 
and their protection against the diet-induced fatty liver disease. These findings also suggest that the FOXO path-
way may serve as a potential therapeutic target for NAFLD.
Figure 5. Fibrosis analysis of liver sections of WT and LTKO mice. Liver fibrosis was analyzed by Sirius Red 
staining (magnification 200X ).
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Materials and Methods
Animals and diets. All animal care and experimental procedures performed in this study were approved 
by the Institutional Animal Care and Use Committee of Indiana University School of Medicine in accordance 
with National Institutes of Health guidelines for the care and use of laboratory animals. Foxo1/3/4 floxed (as 
WT control) and LTKO mice were generated as previously described8. Both males and females were used in 
the experiments. At 2–3 months of age, animals were fed either regular chow (Teklad Diets 2018SX: 24% cal-
ories from protein, 18% calories from fat, and 58% calories from carbohydrate), high-fat diet (HFD, Research 
Diets D12492: 20% calories from protein, 60% calories from fat, and 20% calories from carbohydrate), or moder-
ately high-fat-cholesterol diet (HFC, Research Diets D12109C, 20% calories from protein, 40% calories from fat, 
40% calories from carbohydrate, and 1.25% cholesterol by weight). The feeding experiment was conducted for 3 
months. In the end, the animals were sacrificed for blood and tissue collection. As males and females had a similar 
phenotype, the data presented in this report were primarily collected from the male mice.
Blood chemistry and hepatic lipid analysis. Serum levels of cholesterol, triglycerides, and alanine ami-
notransferase were analyzed using commercial assay kits (Wako USA and Pointe Scientific, respectively) accord-
ing to the manufacture’s manuals. Hepatic triglycerides were extracted and analyzed as previously described8.
RNA isolation and real-time PCR analysis. Total RNAs from the liver tissues were isolated using TRI 
reagent (Sigma) as previously described26. cDNA was synthesized using a reverse transcription kit (Invitrogen). 
Real-time PCR analysis was performed using a SYBR Green PCR kit (Promega). Primer sequences are listed in 
the Supplementary Table 1.
Protein analysis. Liver protein samples were prepared and analyzed as previously described26. The antibod-
ies for the Foxo1, Foxo3, PDGF receptor β , and TGFβ proteins were purchased from Cell Signaling Technology 
(Beverly, MA), and the α -actinin and β -actin antibodies were purchased from Santa Cruz Biotechnology (Dallas, 
TX). The blots were scanned into digital files using a photo scanner (Epson V500).
Histology and IHC analysis. Liver tissue samples were fixed in 10% formalin and processed for embedding 
and sectioning at the Histology Core of Indiana University School of Medicine. Liver sections (5 μ m thickness) 
were stained with hematoxylin and eosin (H&E) or Sirius Red stain (Sigma). Immunohistochemistry analysis was 
performed for MPO, TIMP-1, and α -SMA. The liver tissue sections were deparaffinized, hydrated, and heated in 
1 mM EDTA buffer for antigen retrieval at 100 °C for 5 min, and then treated with normal horse serum for 1 hour. 
Next, the slides were incubated with antibodies against MPO (1:100, Biocare Medical, Concord, CA), TIMP-1 
(1:150, Proteintech, Rosemont, IL), or α -SMA (1:100, Cell Signaling Technology, Beverly, MA), for overnight. 
Figure 6. Expression of genes involving in lipid metabolism. (A–D) Srebp1c, Acc1, Cpt1a (#p < 0.05 for 
Chow-LTKO vs. HFC-LTKO), and Acox2 (#p < 0.05 for Chow-LTKO vs. HFD-LTKO) mRNA levels in WT and 
LTKO livers. Values are expressed as mean ± SEM, n = 4 per group.
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Figure 7. Expression of genes involving in inflammation and fibrogenesis. (A–F) Emr1 (*p < 0.05 for 
Chow-WT vs. Chow-LTKO, #p < 0.05 for HFC-LTKO vs. Chow-LTKO), Ccl2, Pdgfrb (*p < 0.05 for HFC-WT 
vs. HFC-LTKO, #p < 0.05 for HFC-LTKO vs. Chow-LTKO), Tgfb ($p < 0.05 for HFC-WT vs. Chow-WT, 
#p < 0.05 for HFC-LTKO vs. Chow-LTKO), Col1a1 (*p < 0.05 for HFC-WT vs. HFC-LTKO, #p < 0.05 for 
HFC- or HFD-LTKO vs. Chow-LTKO, §p < 0.05 for HFD-LTKO vs. HFC-LTKO), and Timp1 (*p < 0.05 
for LTKO vs. WT in the same diet group, #p < 0.05 for HFD or HFC vs. Chow in the LTKO mice, $p < 0.05 
for HFC vs Chow in the WT mice ) in WT and LTKO livers. Values are expressed as mean ± SEM, n = 4 
per group. (G) Western blot analysis of PDGFRβ and TGFβ in the livers of WT and LTKO mice. The blots 
corresponding to the presented proteins are in the cropped format, and the full-length blots are presented in the 
Supplementary Figure 2.
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After washing with PBS buffer containing 0.05% Tween-20, the tissue sections were incubated with a biotiny-
lated universal pan-specific antibody (PK-7200, Vectastain ABC kit, Vector Laboratories, Burlingame, CA) for 
2 hours. The tissues were subsequently exposed to an avidin-biotin peroxidase complex (Vector Laboratories) for 
1 hour. The peroxidase activity was visualized using a stable diaminobenzidine solution (Vector Laboratories). 
The images were captured using a regular microscope (200X magnification, Leica, Germany).
Quantitative scoring analysis of steatosis and inflammation in liver sections. The quantitative 
scoring of H&E-stain based liver tissue sections was conducted according to the previous methods with slight 
modifications, regarding steatosis56,57 and inflammation58, respectively. Briefly, each section was examined by a 
specialist who was blinded to the sample information and hepatic steatosis and inflammation scores were eval-
uated. The degree of steatosis was graded ‘0’ to ‘4’ based on the average percent of fat-accumulated hepatocyte 
Figure 8. Hepatic neutrophil infiltration. (A) Hepatic inflammation was analyzed by IHC using MPO 
as a marker for neutrophils. The images were captured at a magnification of 200X . (B) The intensity of the 
MPO-positive staining was quantified and normalized to the Chow-WT group. The data are expressed as the 
means ± SEM (n = 4). *p < 0.05 and ***p < 0.001 for WT vs. LTKO, ###p < 0.001 for HFC or HFD vs. Chow in 
LTKO mice. $$$p < 0.001 for HFC or HFD vs. Chow in WT. ¶p < 0.05 for HFC vs. HFD in LTKO mice.
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per field at 200 × magnification under H&E staining (grading 0, < 5% of fat accumulation; grading 1, 5 to 25% of 
fat accumulation; grading 2, 26 to 50% of fat accumulation; grading 3, 51 to 75% of fat accumulation; grading 4, 
> 75% of fat accumulation). The histopathological alterations for inflammation were also scored on 200X magnifi-
cation H&E stained liver sections (grading 0, from normal, absence of pathology to <5% of maximum pathology; 
grading 1, < 10% of maximum pathology: grading 2, 10% to 20% of maximum pathology; grading 3, > 20% of 
maximum pathology).
The intensity of MPO, α -SMA and TIMP-positive signals in IHC images was quantified from the randomly 
selected sections at least five fields of each sample using Image J 1.46 software (NIH, Bethesda, MD). The staining 
intensity was normalized to the Chow-WT group and was presented as fold change.
Statistical analysis. Data were presented as mean ± standard error (SEM). Comparisons between two 
groups were performed using two-tailed student t-test, and comparisons among multiple groups were ana-
lyzed using two-way ANOVA followed by Tukey post hoc test (GraphPad, La Jolla, CA). Differences with a p 
value < 0.05 were considered statistically significant.
Figure 9. Expression of fibrotic markers in the liver. (A and B) Hepatic fibrosis was analyzed by IHC staining 
α -SMA and TIMP-1, respectively. All images were obtained at a magnification of 200X . (C and D) The intensity 
of the α -SMA and TIMP-1-positive staining was quantified and normalized to the Chow-WT group. The data 
are expressed as the means ± SEM (n = 4). *p < 0.05, **p < 0.01, and ***p < 0.001 for WT vs. LTKO, ##p < 0.01 
and ###p < 0.001 for HFC or HFD vs. Chow in LTKO mice. $p < 0.05, $$p < 0.01, and $$$p < 0.001 for HFC or 
HFD vs. Chow in WT. ¶p < 0.05 for HFC vs. HFD in LTKO mice.
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